12/6/2019 8:34:10 AM
Alexion Says Has Not Received Any Indications Of Interest Nor Have Rejected Any Proposals
11/22/2019 8:35:52 AM
Alexion : Japan Approves SOLIRIS For Prevention Of
Relapse In Patients With Neuromyelitis Optica Spectrum Disorder
10/23/2019 6:32:10 AM
Alexion Q3 GAAP EPS $2.08, Up 41% From Prior Year
10/16/2019 6:33:14 AM
Alexion To Acquire Achillion For Initial All-cash Transaction For $6.30/Shr
10/10/2019 4:14:06 PM
Alexion Pharma Appoints As Tanisha Carino As EVP And Chief Corporate Affairs Officer
10/10/2019 7:35:28 AM
Alexion,Stealth Announce Deal For Option To Co-Develop And Commercialize Elamipretide For Mitochondrial Diseases
7/26/2019 8:10:28 AM
Alexion Gets Positive CHMP Opinion For SOLIRIS For Treatment Of NMOSD
7/24/2019 6:33:54 AM
Alexion Q2 GAAP EPS $2.04; Non-GAAP EPS $2.64